PIPAC for Peritoneal Metastases of Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2017

Primary Completion Date

October 1, 2019

Study Completion Date

October 1, 2019

Conditions
Colorectal NeoplasmsPeritoneal NeoplasmsAppendiceal NeoplasmsPeritoneal Carcinomatosis
Interventions
COMBINATION_PRODUCT

repetitive ePIPAC-OX

Instead of standard palliative treatment, enrolled patients receive laparoscopy-controlled electrostatic pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (ePIPAC-OX) (92 mg/m2 body-surface area \[BSA\]) with intravenous leucovorin (20 mg/m2 BSA) and bolus 5-fluorouracil (400 mg/m2 BSA) every six weeks. Four weeks after each procedure, patients undergo clinical, radiological, and biochemical evaluation. ePIPAC-OX is repeated until clinical, radiological, or macroscopic disease progression, after which standard palliative treatment is (re)considered.

Trial Locations (2)

Unknown

Catharina Hospital, Eindhoven

St. Antonius Hospital, Nieuwegein

All Listed Sponsors
lead

Koen Rovers

OTHER

NCT03246321 - PIPAC for Peritoneal Metastases of Colorectal Cancer | Biotech Hunter | Biotech Hunter